Researchers Map a New Cellular Pathway of Cancer Therapy Resistance

Tuesday, January 3, 2017

“Nuclear localized RTKs can mediate resistance to therapeutics used to treat cancer, such as radiation therapy, chemotherapy or antibody-based therapies that directly block RTKs on the cell surface,” said Dr. Toni Brand, a former UW-Madison CMP graduate student in Dr. Deric Wheeler's lab and lead author of the study. “We wanted to identify how RTKs move to the nucleus so that we can design therapies to block their transport and hopefully enhance the efficacy of antibody-based therapies in the future.”